Hookipa Pharma Revenue and Competitors

Vienna, Austria

Location

$149.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Hookipa Pharma's estimated annual revenue is currently $19.7M per year.(i)
  • Hookipa Pharma's estimated revenue per employee is $108,950
  • Hookipa Pharma's total funding is $149.3M.

Employee Data

  • Hookipa Pharma has 181 Employees.(i)
  • Hookipa Pharma grew their employee count by 6% last year.

Hookipa Pharma's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
VP Human ResourcesReveal Email/Phone
4
VP Clinical OperationsReveal Email/Phone
5
VP Immuno-Oncology, Clinical Research & Development at HOOKIPA BiotechReveal Email/Phone
6
VP, Clinical Development- Infectious DiseaseReveal Email/Phone
7
VP, Head Investor Relations and Corporate CommunicationsReveal Email/Phone
8
VP - Preclinical & Translational ResearchReveal Email/Phone
9
VP - VirologyReveal Email/Phone
10
Head CMC Program ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$19.7M1816%$149.3MN/A
#2
$15.3M998%N/AN/A
#3
$2.3M15-6%N/AN/A
#4
$15.3M998%N/AN/A
#5
$10.1M65-8%N/AN/A
#6
$15.3M998%N/AN/A
#7
$9.6M622%N/AN/A
#8
$5.1M3394%N/AN/A
Add Company

What Is Hookipa Pharma?

Hookipa Pharma Inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. With this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. Our Arenavirus technologies, Vaxwave®, a replication-deficient viral vector, and TheraT®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and CD8+ T cells. Both, Vaxwave® and TheraT®, can be administered repeatedly while maintaining their efficacy. TheraT® induced CD8+ T cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive T cell therapy. Hookipa?s ?off-the shelf? viral vectors are administered systemically. They target dendritic cells in vivo and activate the immune system. In immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). At Hookipa we have successfully completed a Phase 1 trial of a Vaxwave®-based prophylactic vaccine to protect against cytomegalovirus (CMV) infections. A proof-of concept trial in solid organ transplant patients will start imminently. We have forged a landmark partnership with Gilead Sciences Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. We are building a proprietary immune-oncology pipeline by targeting TheraT® towards HPV+ head and neck squamous cell carcinoma and prostate cancer.

keywords:N/A

$149.3M

Total Funding

181

Number of Employees

$19.7M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Hookipa Pharma News

2022-04-17 - What is the Market's View on Hookipa Pharma Inc (HOOK) Stock's Price and Volume Trends Friday?

HOOK receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator. Sentiment Score - ,bearish. Hookipa Pharma Inc has a Bearish...

2022-04-17 - HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of ...

NEW YORK and VIENNA, Austria, April 20, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a new...

2022-04-13 - HOOKIPA Pharma Shares Increase 15% on Favorable Preclinical Data

HOOKIPA Pharma Inc. shares rose 15% to $2.03 as the company reported positive preclinical data for its cancer-focused immunotherapies.

2021-10-14 - HOOKIPA Pharma : announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in Oncology

Comprehensive review highlights potential of HOOKIPA’s versatile arenavirus platform as a new immunotherapy strategy to address critical unmet needs in cancer Pre-clinical and clinical data showcase potent, tumor-specific CD8+ T cell responses following intravenous administration of arenaviral ...

2021-09-16 - HOOKIPA Pharma : announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA (pembrolizumab) in patients with advanced head and neck cancers

NEW YORK and VIENNA, Austria - HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced it has entered into a clinical collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ., ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A18411%N/A
#2
$29.7M186-4%N/A
#3
N/A18935%N/A
#4
$42.9M1917%N/A
#5
N/A1927%N/A